FAST generics act re-introduced to increase generics competition

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

FAST generics act re-introduced to increase generics competition

Home/Policies & Legislation | Posted 21/08/2015 0 Post your comment

On 18 June 2015, US lawmakers Steve Stivers and Peter Welch re-introduced the Fair Access for Safe and Timely (FAST) Generics Act to increase consumer access to generics, boost market competition and ultimately save consumers money.

According to Rep Stivers, the bill ‘closes federal loopholes to ensure consumers have faster access to less costly generics by increasing market competition and eliminating bureaucratic red tape’.

The bill aims to solve the problems generics companies often have getting their hands on samples of the originator drug in order to carry out bioequivalence trials. It is believed that some companies are abusing US Food and Drug Administration safety programmes, such as the risk evaluation and mitigation strategy (REMS), as a reason to withhold access to drug samples for generics makers. This results in anticompetitive practices and increased costs for both payers and patients.

Abuse of REMS and REMS-like programmes has been estimated to cost the American healthcare system and its patients US$5.4 billion annually. Should these practices extend to biosimilars, US$140 million in savings would be lost for every US$1 billion in biologicals sales, according to a study by Matrix Global Advisors.

The FAST Generics Act includes common sense reforms to close these loopholes and address the most common abuses of REMS and non-REMS restricted access programmes.

The Generic Pharmaceutical Association, which represents the generics industry in the US, has applauded the congressmen for introducing the bill, which they hope will close the loopholes for abuse of REMs and non-REMs restricted access programmes.

Generics companies have even had to resort to bring lawsuits against originator companies in the past in order to get samples of the originator drug. While the US Federal Trade Commission has come out in support of generics companies trying to get hold of brand-name drugs in order to make generic versions [1].

Reference
1. GaBI Online - Generics and Biosimilars Initiative. US FTC sides with generics makers over drug samples [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 21]. Available from: www.gabionline.net/Policies-Legislation/US-FTC-sides-with-generics-makers-over-drug-samples

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Rep Stivers, US House